Boehringer Ingelheim announced today new data from the pivotal Phase II Effisayil™ 1 trial, presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Boston. The Effisayil™ 1 trial, recently published in The New England Journal of Medicine, showed significant clearance of skin pustules in patients with generalized pustular psoriasis (GPP) flares within…

eTurboNews tala e mo na'o le au fai saofaga. O le lesitala o saʻoloto.
O lo'o fa'aulufale mai iinei Kiliki iinei e lesitala FREE

OA MEA E AVEA MAI LENEI TUSI:

The Effisayil™ 1 trial, recently published in The New England Journal of Medicine, showed significant clearance of skin pustules in patients with generalized pustular psoriasis (GPP) flares within….
Na faalauiloa e Boehringer Ingelheim i aso nei ni faʻamatalaga fou mai le taua o le Phase II Effisayil ™ 1 faʻataʻitaʻiga, na tuʻuina atu i le 2022 American Academy of Dermatology (AAD) Fonotaga Faaletausaga i Boston.
O le lesitala e leai se totogi.